Revenue for ultrasound imaging manufacturer EndoSonics was $48.2 million at the end of 1999, up from $44.1 million in 1998. Revenue for the fourth quarter, however, was only $11.7 million, compared with $13.3 million for the fourth quarter of the
Revenue for ultrasound imaging manufacturer EndoSonics was $48.2 million at the end of 1999, up from $44.1 million in 1998. Revenue for the fourth quarter, however, was only $11.7 million, compared with $13.3 million for the fourth quarter of the previous year. For the fourth quarter of 1999 the company reported a net loss of $1 million, compared to a net gain of $2.6 million in the fourth quarter of 1998.
The Rancho Cordova, CA-based company made significant gains through direct sales in the companys two largest markets, the U.S. and Germany, said president and CEO Reinhard J. Warnking.
In the last half of the year, EndoSonics sales declined sharplysomething analysts did not predict. For example, disappointing European sales contributed to lower than expected financial results in the third quarter of 1999. Because EndoSonics European distributor, Jomed International, did not sell products as briskly as had been anticipated, the company reported it would cancel one of two distribution agreements with Jomed (SCAN 10/13/99). This week EndoSonics announced that Jomed will continue acting as its distributor in smaller European markets, while other distributors will handle the business in Japan and some larger markets.
The company has entered into an alliance with North American Scientific, a leading developer of brachytherapy products, to develop the radiation source for EndoSonics intravascular ultrasound-guided radiation catheter (SCAN 1/19/00). EndoSonics hopes to file an application with the FDA for this device in the first half of this year.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.